Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David Golan
AddedMar 9, 2023
UpdatedMay 31, 2026
David Golan

David Golan

Co-Founder & CTO, Viz.ai

CrunchbaseLinkedIn

David Golan's Career

Viz.ai
Viz.ai

San Francisco, CA, US

Co-Founder & CTO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David Golan's Career

Viz.ai
Viz.ai
Late Stage Private$331.6M4132016San Francisco, CA, US
Co-Founder & CTO· C-Suite · Management

Recent news

News and Press releases - Viz.aiNews · 2024
Viz.ai Closes 2025 with Record Scale and Patient ImpactNews · 2024
Viz.ai Launches Viz Assist: The First Multimodal AI Agent ...News · 2024

Leadership at Viz.ai

Dr Chris MansiDr Chris MansiCo-Founder & CEO
Kurt BlasenaKurt BlasenaChief Revenue Officer
Rory O'DriscollRory O'DriscollBoard Member
Neil ShahNeil ShahBoard Member
Chris MansiChris MansiCo-Founder
Mamoon HamidMamoon HamidBoard Member

Similar to Viz.ai

PathAIPathAIBoston, MA, USest. 2016PathAIBoston, MA, US · est. 2016

An AI-powered pathology platform that increases the accuracy of diagnosis and efficacy of treatment.

Late Stage Private · $355.2M360
EnliticEnliticSan Francisco, CA, USDiagnostics, Healthcareest. 2014EnliticSan Francisco, CA, US · est. 2014

A pioneer in medical deep learning that leverages algorithms to improve healthcare diagnosis.

Series B · $65M64
PathologyWatchPathologyWatchPathology Softwareest. 2017PathologyWatchest. 2017

An intuitive and easy-to-implement digital pathology solution for dermatologists and labs.

Venture · $54.6M48
PaigePaigeNew York City, NY, USAI Diagnostics, Softwareest. 2018PaigeNew York City, NY, US · est. 2018

A clinical AI company that utilizes computational pathology for cancer discovery and treatment.

Series C · $220M145

David Golan's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder & CEO · DiDiHong Eun-taekHong Eun-taekCEO · KakaoChoi Soo-yeonChoi Soo-yeonCEO · NaverMickey MikitaniMickey MikitaniCEO · RakutenKoji ShibataKoji ShibataCEO · ANA HoldingsNobuo HayasakaNobuo HayasakaCEO · KioxiaTaek-Jin KimTaek-Jin KimCo-Founder & CEO · Ncsoft

People Similar to David Golan

Daniel GershuniDaniel GershuniCo-Founder & COO · OwnBackupJony ShlomoffJony ShlomoffCo-Founder & CTO · Adaptive ShieldAviv DrorAviv DrorCo-Founder & CPO · One AIYoav ShohamYoav ShohamCo-Founder & Co-CEO · AI21 LabsAriel BerkmanAriel BerkmanCo-Founder & CTO · OwnBackupYochai LeviYochai LeviCo-Founder & CMO · One AI